McDermott says that he started seeing a dermatologist when he was in his 20s at the recommendation of his parents.

In contrast, the sensitivity of IFSH for predicting final surgical margin status was low, at 21.7%. This indicates that while ...

In a report released yesterday, Judah Frommer from Morgan Stanley maintained a Buy rating on Bicara Therapeutics Inc. (BCAX – Research Report), ...

A pioneering study has unveiled the Au-HN-1 nanosystem, a cutting-edge approach that promises to transform the diagnosis and ...

The trial builds off the company’s previous Phase Ia/II trial that saw an estimated survival rate of 52.4% at 24 months in ...

A pioneering study has unveiled the Au-HN-1 nanosystem, a cutting-edge approach that promises to transform the diagnosis and ...

The Au-HN-1 nanosystem represents a breakthrough in TSCC treatment, integrating targeted photothermal therapy with advanced ...

H.C. Wainwright analyst Robert Burns has reiterated their bullish stance on BCAX stock, giving a Buy rating on January 22.Invest with ...

Rakuten Medical initiates global phase 3 trial of ASP-1929 photoimmunotherapy in combo with pembrolizumab to treat recurrent head and neck cancer: United States Saturday, January ...

Eleven drugs are poised to reach blockbuster status, dramatically improving patient outcomes on a global scale.

Exelixis (EXEL) has recently gained traction in the rapidly growing oncology market with its promising pipeline and strong ...